Lexmark International (LXK) 37.40 $LXK Lexmark

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Lexmark International (LXK) 37.40 $LXK

Lexmark Healthcare Delivers a More Connected and Complete Patient Record
PRWeb - Wed Jun 01, 11:04AM CDT
News Facts Lexmark International, a global technology leader, today announced the availability of several new and enhanced enterprise imaging and enterprise content management (ECM) offerings -- all designed to help healthcare delivery organizations (HDOs) consolidate health data and images, streamline clinical workflows, and complete the patient record. PACS Redefined is a modular suite of software and services that provide a cost-effective alternative to traditional PACS. When implemented as part of an enterprise imaging strategy, PACS Redefined can free HDOs from vendor lock-in, break down departmental imaging silos, streamline image-sharing and access throughout the organization, and image-enable an EHR or other core clinical system. Key components of PACS Redefined include: o Lexmark VNA (vendor neutral archive) o NilRead Interpretation Enterprise Viewer o Clario Worklist Management Software Mobile for Healthcare Solutions is designed to securely transfer photographs and clinical images captured on iOS devices to a central ECM, PACS, VNA or EHR repository. Integration with Epic's Haiku / Canto is available along with the ability to submit images within Integrating the Healthcare Enterprise's (IHE), Cross-Enterprise Document Sharing (XDS) profile. ECM for Healthcare Point-of-Care Capture is an enhanced solution designed with the insight of Lexmark Healthcare customers to ensure ease-of-use on the hospital floors to accommodate the fast-paced environment of patient care. Health systems focused on value-based care initiatives such as HIMSS Level 7 and workflow optimization will benefit greatly. Lexmark has also collaborated with Microsoft to outline best practices for the Microsoft Azure deployment of Acuo VNA in a hybrid deployment model owned and managed by the customer. These enhanced cloud capabilities provide HDOs with the flexibility needed to address growing cost and scalability concerns. Healthcare has a mission to improve patient outcomes while better managing costs. Lexmark makes it easier for healthcare enterprises to accomplish that mission by eliminating the inefficiency, complexity and roadblocks that prevent easy access to the documents and medical image content needed throughout that journey. Lexmark Healthcare was named 2015 North American Company of the Year in Healthcare Content Management by Frost & Sullivan, based on demonstrated excellence in growth, innovation and leadership. Healthcare Content Management (HCM) is a comprehensive approach to centralizing disparate patient documents and medical images throughout a healthcare enterprise. The strategy focuses on providing HDOs with all the technology needed to connect, manage, view and share patient content when and where it is needed. It encompasses our 20+ year, market-leading ECM for Healthcare, VNA, Enterprise Viewer and PACSGEAR image connectivity solutions. A health system can pursue each solution independently or in a comprehensive manner to advance their healthcare mission according their needs and budget. Supporting Quotes "Healthcare organizations have made massive investments in EMR solutions," said Nadim Daher, principal analyst, medical imaging and imaging informatics, Frost & Sullivan. "Access to patient information, however, is still hindered by the disconnected silos of patient content scattered throughout the healthcare enterprise. Lexmark's ability to provide a unified approach for augmenting and optimizing the EMR's capabilities is a major step toward interoperability and availability of healthcare content. The combination of best-of-breed capabilities in Lexmark's healthcare solutions portfolio into a comprehensive HCM platform is the prime example, in today's market, of the IT foundation needed to close the loop on a holistic EMR strategy." "These new offerings expand and enhance our healthcare software and solution portfolio based on feedback from more than 3,000 of our healthcare customers and evolving market needs," said Reynolds C. Bish, vice president of Lexmark and president of Lexmark Enterprise Software. "This supports our mission to help healthcare customers take ownership of data, improve business operations, enhance information visibility, and provide access to all patient-centered information at the right time, in the right place, and always in context of the right patient." Supporting Resources Explore Lexmark healthcare solutions http://www.incontextmag.com/topics/healthcare.html Stay in touch with Lexmark Healthcare on LinkedIn
LXK: 37.40 (-0.16)

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of Directors of Lexmark International, Inc. Regarding the Sale of the Company to a Consortium - LXK
PR Newswire - Mon May 09, 12:44PM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Lexmark International, Inc. (NYSE: LXK) ("Lexmark" or "the Company" in connection with the sale of the Company to a consortium led by Apex Technology Co. Ltd. and PAG Asia Capital. Under the terms of the transaction, Lexmark shareholders will receive $40.50 in cash for each share of Lexmark stock they own.
LXK: 37.40 (-0.16)

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Lexmark International, Inc. Buyout
BusinessWire - Wed May 04, 3:41PM CDT
Rigrodsky & Long, P.A.:
LXK: 37.40 (-0.16)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation as to Whether the Sale of Lexmark International, Inc. for $40.50 to a Consortium is Fair to Shareholders
BusinessWire - Mon May 02, 3:28PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
LXK: 37.40 (-0.16)

Lexmark (LXK) Misses on Q1 Earnings; Revenues Down Y/Y
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 11:00AM CDT
Lexmark International Inc. (LXK) started 2016 on a dismal note with reporting lower than expected earnings per share for the first-quarter 2015 level.
CAJ: 28.32 (-0.23), WDC: 46.28 (-0.57), HPQ: 13.03 (-0.47), LXK: 37.40 (-0.16)

Lexmark's (LXK) Q1 Earnings Miss Estimates
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 7:51AM CDT
Lexmark International Inc. (LXK) posted lower-than-expected first-quarter 2016 results.
LXK: 37.40 (-0.16)

Lexmark reports 1Q loss
Automated Insights - Wed Apr 27, 6:34AM CDT
LEXINGTON, Ky. (AP) _ Lexmark International Inc. (LXK) on Wednesday reported a first-quarter loss of $39.4 million, after reporting a profit in the same period a year earlier.
LXK: 37.40 (-0.16)

Lexmark reports first quarter results
PR Newswire - Wed Apr 27, 6:00AM CDT
Lexmark International, Inc. today announced financial results for the first quarter of 2016.
LXK: 37.40 (-0.16)

INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation as to Whether the Sale of Lexmark International, Inc. for $40.50 to a Consortium is Fair to Shareholders
BusinessWire - Tue Apr 26, 3:41PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
LXK: 37.40 (-0.16)

INVESTOR ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Lexmark International, Inc. and Encourages Shareholders to Contact the Firm for Additional Information
BusinessWire - Tue Apr 26, 2:18PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Lexmark International, Inc. (Lexmark or the "Company" (NYSE: LXK) relating to the proposed buyout of the Company by a consortium of investors led by Apex Technology Co., Ltd. and PAG Asia Capital.
LXK: 37.40 (-0.16)

The Zacks Analyst Blog Highlights: Intel, Advanced Micro Devices, Alphabet, Lexmark and Amazon
Zacks Equity Research - Zacks Investment Research - Tue Apr 26, 8:30AM CDT
The Zacks Analyst Blog Highlights: Intel, Advanced Micro Devices, Alphabet, Lexmark and Amazon
AMZN: 715.24 (-2.67), AMD: 4.40 (+0.08), GOOGL: 731.88 (-1.31), INTC: 32.17 (+0.13), LXK: 37.40 (-0.16)

NXP Semiconductors (NXPI) Q1 Earnings & Revenues Beat
Zacks Equity Research - Zacks Investment Research - Tue Apr 26, 8:10AM CDT
NXP Semiconductors NV (NXPI) reported first quarter fiscal 2016 adjusted earnings per share of 86 cents per share, which came ahead of the Zacks Consensus Estimate of 83 cents per share.
LSCC: 5.64 (-0.04), XLNX: 46.32 (-0.41), NXPI: 87.40 (-1.03), LXK: 37.40 (-0.16)

Lexmark announces date of first quarter 2016 earnings release
PR Newswire - Tue Apr 26, 7:00AM CDT
Lexmark International, Inc. plans to announce first quarter 2016 earnings before the opening of the New York Stock Exchange on Wednesday, April 27, 2016. The earnings release will be available on Lexmark's investor relations website at http://investor.lexmark.com.
LXK: 37.40 (-0.16)

Technology Stock Roundup: In The Thick of Earnings Season
Sejuti Banerjea - Zacks Investment Research - Mon Apr 25, 1:32PM CDT
Technology earnings started pouring in last week with more misses than beats. As a result, shares have mostly moved down past the announcements.
NFLX: 93.85 (+0.10), AMZN: 715.24 (-2.67), YHOO: 36.47 (-0.36), AMD: 4.40 (+0.08), GOOGL: 731.88 (-1.31), INTC: 32.17 (+0.13), MSFT: 50.14 (-1.34), LXK: 37.40 (-0.16)

Lexmark (LXK) Q1 Earnings: Surprise in Store for the Stock?
Zacks Equity Research - Zacks Investment Research - Mon Apr 25, 5:55AM CDT
Lexmark International Inc. (LXK) is expected to report first-quarter 2016 results on Apr 26.
BYD: 18.47 (-0.37), BNFT: 39.60 (+0.37), WDC: 46.28 (-0.57), LXK: 37.40 (-0.16)

SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Lexmark International, Inc.
BusinessWire - Fri Apr 22, 8:15PM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Lexmark International, Inc. ("Lexmark" or "the Company" (NYSE: LXK) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Apex Technology Co., Ltd. and PAG Asia Capital ("Apex" .
LXK: 37.40 (-0.16)

Fitch Places Lexmark's Ratings on Negative Watch
BusinessWire - Fri Apr 22, 1:51PM CDT
Fitch Ratings has placed Lexmark International Inc. (Lexmark) on Rating Watch Negative (RWN) following the announced acquisition of Lexmark by a consortium of companies led by Chinese firm Apex Technology Co., Ltd. and PAG Asia Capital for $40.50 per share in an all cash transaction with an enterprise value of approximately $3.6 billion net of cash. A full list of rating actions follows at the end of this release.
LXK: 37.40 (-0.16)

DST Systems (DST) Tops Q1 Earnings & Revenue Estimates
Zacks Equity Research - Zacks Investment Research - Fri Apr 22, 9:42AM CDT
DST Systems Inc. (DST) reported first-quarter 2016 non-GAAP earnings of $1.61 per share, beating the Zacks Consensus Estimate of $1.46.
FISV: 105.61 (-0.77), IBM: 151.28 (-1.09), DST: 115.87 (-2.03), LXK: 37.40 (-0.16)

Lexmark Stock Soars Following Announcement of Its Buyout
Zacks Equity Research - Zacks Investment Research - Thu Apr 21, 4:56PM CDT
Lexmark International Inc. (LXK) has agreed to be acquired by a consortium led by Apex Technology Co., Ltd. (Apex) and PAG Asia Capital (PAG).
CAJ: 28.32 (-0.23), GS: 148.63 (-1.26), WDC: 46.28 (-0.57), LXK: 37.40 (-0.16)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 230

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 225

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
DIRECTV Bags New NHL Deals: Stakes for Sports Fans

Updated Category News Views 308

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 412

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Firefox Champions Privacy with Iconic Internet Campaign

Updated Category News Views 106

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 130

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 288

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
CapCut's Role in AI-Assisted Small Biz Marketing

Updated Category News Views 131

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Continue Reading
Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 127

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 134

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading

Top 5 Most Recently Viewed Articles

Expanding Horizons: Future of IVD Contract Manufacturing

Updated Category News Views 117

The Growing Landscape of IVD Contract Manufacturing The in vitro diagnostics (IVD) contract manufacturing market is on the brink of significant expansion, anticipated to reach a staggering USD 39.74 billion by 2031. This growth represents a compounded annual growth rate (CAGR) of 11.60% from 2024 to 2031, driven chiefly by the needs of the healthcare industry to keep pace...

Continue Reading
Citi Upgrades AerCap Holdings Price Target to $117 Amid Strong Performance

Updated Category News Views 79

Citi Upgrades AerCap Holdings Price Target Citi has recently updated its outlook on AerCap Holdings (NYSE:AER), raising the price target to $117 from $113. This move reflects Citi's confident stance on the aircraft leasing company's financial health within the aviation sector. By reaffirming their buy rating, the firm signals strong expectations for AerCap's growth...

Continue Reading
LG Energy Solution Reports Strong Q2 2025 Financial Performance

Updated Category News Views 750

LG Energy Solution Achieves Remarkable Financial Milestones In a significant announcement, LG Energy Solution has revealed its performance for the second quarter of 2025, detailing impressive results that demonstrate the company's resilience and strategic focus on growth. With consolidated revenue of KRW 5.6 trillion and an operating profit of KRW 492.2 billion, the...

Continue Reading
Genpact Shines as a Leader in Sustainability Recognition

Updated Category News Views 264

Genpact's Sustainable Initiatives Gain Global Recognition Recently, Genpact (NYSE: G), an advanced technology services provider, received significant acclaim for its commitment to sustainability. Being featured in TIME's prestigious list of the World's Best Companies in Sustainable Growth for 2025 showcases their dedication to ethical business practices and innovation. A...

Continue Reading
Medical Express Ambulance Faces Data Breach Investigation

Updated Category News Views 344

Understanding the Data Breach Investigation Edelson Lechtzin LLP, a prominent class action law firm, is currently looking into data privacy concerns affecting customers of Medical Express Ambulance, Inc. (MedEx). MedEx has reported potential unauthorized access to its network, raising significant alarm regarding the safety of customer data. Medical Express Ambulance, Inc....

Continue Reading